The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Those with Hepatitis B or C Need Hepatitis A Immunity

Back to News Homepage

Next

Could New HCV Drugs Excessive Pill Intake Hinder Compliance?

Boceprevir Approval Means Better Hep C Treatment Finally Available

May 16, 2011

Print this page

As the first FDA approved Hepatitis C protease inhibitor, boceprevir (Victrelis) has cleared the final hurdle and can now improve the general public’s odds for beating the Hepatitis C virus.

Boceprevir Wins FDA Approval to Treat Hepatitis C

By Emily P. Walker, Washington Correspondent, MedPage Today

Published: May 13, 2011

WASHINGTON — The FDA has approved the investigational drug boceprevir (Victrelis), to be used in combination with peginterferon and ribavirin, to treat hepatitis C genotype 1.

Boceprevir, made by Merck, will be the first HCV protease inhibitor to reach market and is expected to be a major advance in treating the disease, which affects between three and four million people in U.S.

Continue reading this entire article:
http://www.medpagetoday.com/InfectiousDisease/Hepatitis/26469

No Comments - be the first!
Share
Share

Previous

Those with Hepatitis B or C Need Hepatitis A Immunity

Back to News Homepage

Next

Could New HCV Drugs Excessive Pill Intake Hinder Compliance?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.